Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Volcon Raises $27.2M Via Debt Offering

Volcon Inc (NASDAQ:VLCN) has signed a securities purchase agreement to issue an investor $27.2 million of convertible senior notes due 2024.…
byShivani Kumaresan
August 22, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • Volcon Inc (NASDAQ:VLCN) has signed a securities purchase agreement to issue an investor $27.2 million of convertible senior notes due 2024.
  • The agreement also includes accompanying warrants to purchase approximately 9.1 million shares of common stock with an initial exercise price of $2.85.
  • The initial conversion price will be $2.25 per share of common stock. Each of the Notes will include an original issue discount of 8.0%.
  • The notes are expected to mature on February 24, 2024.
  • Price Action: VLCN shares are trading lower by 22.31% at $1.88 on the last check Monday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Astrazeneca To Present 19 Abstracts, Including 10 Oral Presentations And Five Late-breaking Presentations, At The European Society Of Cardiology Congress

By Charles Gross
August 21, 5:03 AM
AstraZeneca will present 19 abstracts, including 10 oral presentations and five late-breaking presentations, at the European Society of Cardiology (ESC) Congress from 25-28 August 2023, which includes data highlightingAstraZeneca will present 19 abstracts, including 10 oral presentations and five late-breaking presentations, at the European Society of Cardiology (ESC) Congress from 25-28 August

AZN

Read More

Day One Announced Sunday Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma

By Charles Gross
January 9, 6:42 AM
Day One Biopharmaceuticals (NASDAQ: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced positive topline results from the ongoing, open-label, pivotal Phase 2 FIREFLY-1 trial evaluating the invest

DAWN